Methylcellulose
Explore a selection of our essential drug information below, or:
Identification
- Summary
Methylcellulose is a compound used as a bulk forming laxative and is not an approved medication.
- Brand Names
- Citrucel
- Generic Name
- Methylcellulose
- DrugBank Accession Number
- DB11228
- Background
Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values are 1.3 2.6. Methyl cellulose is a hydrophilic white powder in pure form and dissolves in cold (but not in hot) water, forming a clear viscous solution or gel. It is available under a variety of trade names as a treatment for constipation. Like cellulose, it is not digestible, not toxic, and not allergenic
- Type
- Small Molecule
- Groups
- Approved
- Synonyms
- Cellulose methyl
- cellulose methyl ether
- Cellulose methylate
- Methyl cellulose
- methylated cellulose
- Methylcellulose
- Methylcellulosum
- Metilcelulosa
- External IDs
- E461
Pharmacology
- Indication
Solutions containing methyl cellulose are used as substitute for tears or saliva if the natural production of these fluids is disturbed. It is also used or constipation, diverticulosis, hemorrhoids and irritable bowel syndrome. Used in the manufacture of capsules in nutritional supplements. Its edible and nontoxic properties provide a vegetarian alternative to the use of gelatin.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Constipation ••• ••• Used in combination to treat Dry eye syndrome (des) Combination Product in combination with: Benzalkonium (DB11105) ••• ••• •••••••• • ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
It increases the bulk in your stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.
- Mechanism of action
Methylcellulose absorbs water in the gastrointestinal lumen thereby increasing the bulk of the stool. This leads to distension and stimulation of peristalsis. The ability of methylcellulose to absorb water may contribute to its efficacy in the management of diarrhea by once again increasing the bulk and consistency of the stool.
- Absorption
Cellulose derivatives considered in this report are virtually unabsorbed and little or no degradation of absorbed and little or no degradation of absorbable products occurs in the human digestive tract. In humans, virtually 100 percent of orally ingested methyl cellulose can be recovered in the feces withihn four days, indicating that absorption does not occur.
- Volume of distribution
accumulation in liver, spleen, lymph nodes, kidney, and vascular walls.
- Protein binding
Not Available
- Metabolism
Reported that when methylcellulose was given iv to dog and rabbit , aside from effect upon circulating blood, inability of body to degrade substance led to its retention & accumulation in liver, spleen, lymph nodes, kidney, and vascular walls.
- Route of elimination
When swallowed they are not absorbed to any appreciable degree and appear unchanged in feces.
- Half-life
4.2 minutes
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Organism: Mouse Test type: LD50 Route : Intraperitoneal Reported Dose: 275gm/kg ( 275000mg/kg) Toxic Effect: Details of toxic effects not reported other than lethal dose value
Organism: Mouse Test type: LDLo Route : Intravenous Reported Dose: 1gm/kg ( 1000mg/kg) Toxic Effect: Details of toxic effects not reported other than lethal dose value
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Methylcellulose. Aclidinium The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Methylcellulose is combined with Alloin. Amantadine The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Amantadine. - Food Interactions
- Take with a full glass of water.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Methylcellulose (100 MPa.s) 4GFU244C4J 9004-67-5 Not applicable Methylcellulose (15 MPa.s) NPU9M2E6L8 9004-67-5 Not applicable Methylcellulose (1500 MPa.s) Z944H5SN0H 9004-67-5 Not applicable Methylcellulose (25 MPa.s) BI55GG2WLI 9004-67-5 Not applicable Methylcellulose (400 MPa.s) O0GN6F9B2Y 9004-67-5 Not applicable Methylcellulose (4000 MPa.s) MRJ667KA5E 9004-67-5 Not applicable - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Best Choice Fiber Therapy Tablet 500 mg/1 Oral Best Choice (Valu Merchandisers Company) 2019-04-19 Not applicable US CDMA Fiber Therapy Tablet 500 mg/1 Oral Chain Drug Marketing Association 2019-04-19 Not applicable US Citrucel Powder, for solution 2 g/19g Oral GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 2010-09-16 Not applicable US Citrucel Powder, for solution 2 g/10.2g Oral GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 2010-09-16 Not applicable US Citrucel Tablet 500 mg/1 Oral GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 2010-02-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Slim-mint Gum Methylcellulose (44 mg / gum) + Benzocaine (4 mg / gum) Gum, chewing Oral Stella Pharmaceutical Canada Inc. 1978-12-31 1998-08-13 Canada
Categories
- ATC Codes
- A06AC06 — Methylcellulose
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 9004-67-5
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Treatment Cornea Ulcer 1 somestatus stop reason just information to hide 4 Completed Treatment Allergic Conjunctivitis (AC) 2 somestatus stop reason just information to hide 4 Completed Treatment Dry Eyes 1 somestatus stop reason just information to hide 4 Completed Treatment Irritable Bowel Syndrome (IBS) 1 somestatus stop reason just information to hide 4 Completed Treatment Ophthalmopathy , Lacrimal System 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Oral 2 g/10.2g Powder, for solution Oral 2 g/19g Solution Oral 1.8 % Tablet Oral 500 mg/1 Solution / drops Ophthalmic Solution / drops Ophthalmic 10 mg/15mL Solution / drops Ophthalmic 1 % Powder Oral 2 g / 19 g Powder Oral 2 g / 10.2 g Tablet Oral 500 mg Gum, chewing Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at October 21, 2024 08:50